Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

8837 items
8:16 AM, May 09, 2018  |  BC Innovations | Distillery Therapeutics

Hepatic

INDICATION: Liver disease In vitro and mouse studies identified a peripherally restricted purine-based CNR1 antagonist that could help treat alcoholic liver steatosis. Chemical synthesis of analogs of the CNR1 antagonist otenabant and in vitro binding assays...
8:16 AM, May 09, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggest farnesyl transferase inhibitors plus the oncolytic alphavirus M1 could help treat colorectal and pancreatic cancers. In a human colorectal cancer cell line treated with alphavirus M1, co-treatment with...
8:16 AM, May 09, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Dermatology Mouse and cell culture studies suggest RHBDF2 inhibition or sulforaphane could help treat palmoplantar keratoderma. In a mouse model of palmoplantar keratoderma of the footpad, knockout of RHBDF2 decreased footpad epidermis thickness compared with...
9:18 AM, May 03, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/metabolic

INDICATION: Endocrine/metabolic Mouse studies suggest KHK inhibitors could help treat hereditary fructose intolerance. In a mouse model of hereditary fructose intolerance, systemic KHK knockout decreased hypoglycemia, fibrosis and inflammation in the liver compared with normal KHK...
9:18 AM, May 03, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies suggest a biotinoyl-deoxyadenosine-based inhibitor of M. tuberculosis BirA could help treat tuberculosis (TB) and reduce drug resistance. In M. tuberculosis cultures, a previously reported biotinylated analog of deoxyadenosine that...
9:17 AM, May 03, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest the PPARγ agonist Avandia rosiglitazone could help treat melanoma. In a mouse model of melanoma, Avandia plus an irradiated GM-CSF-secreting tumor cell vaccine and an anti-CTLA-4 mAb decreased tumor incidence and...
9:17 AM, May 03, 2018  |  BC Innovations | Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting AEBP1 could help treat non-alcoholic steatohepatitis (NASH). In liver samples from NASH patients, hepatic stellate cell (HSC) levels of AEBP1 were higher than in samples...
4:31 PM, May 01, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus; viral infection Cell culture studies suggest two sialylated IGHA1 isotype mAbs targeting HA could help treat influenza and Newcastle disease. The IGHA1 isotype mAbs consist of the variable regions of two previously identified...
4:31 PM, May 01, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Spinal muscular atrophy (SMA) Cell culture and mouse studies suggest inhibiting SQSTM1 could help treat SMA, which is caused by SMN1 mutations. In motor neuron cells derived from a mouse model of SMA or...
4:30 PM, May 01, 2018  |  BC Innovations | Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis In vitro and mouse studies identified a hydroxamic acid-based ENPP2 inhibitor that could help treat pulmonary fibrosis. Chemical synthesis and in vitro testing in enzymatic activity assays of hydroxamic acid analogs yielded a...

Pages